Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare clinical response (complete response and partial response) by RECIST) rates by
RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy